The Side-Out Foundation

MAKING BREAST CANCER A MANAGEABLE DISEASE (SIMILAR TO DIABETES) TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION & CUTTING-EDGE TACTICS. THE SIDE-OUT FOUNDATION IS A 501(C)(3) NON-PROFIT ORGANIZATION, FOUNDED IN 2004 BY RICHARD AND BRYANT DUNETZ, TO EMPOWER A NEW GENERATION OF ADVOCATES, MAKE SIGNIFICANT AND IDENTIFIABLE IMPACT ON THE WAY BREAST CANCER IS TREATED, AND GIVE THOSE LIVING WITH METASTATIC BREAST CANCER (MBC) MORE TOMORROWS.SINCE ITS INCEPTION, THE FOUNDATION HAS (I) BUILT EDUCATIONAL AND COMMUNITY-DRIVEN PROGRAMS FOCUSED ON TEACHING ADVOCACY TO THE NEXT GENERATION OF CHANGEMAKERS, EQUIPPING THEM WITH SKILLS AND TOOLS TO SUPPORT SIDE-OUT'S MISSION, AS WELL AS ANY CAUSE THEY WISH TO CONNECT TO IN THEIR FUTURE; (II) FORGED GROUNDBREAKING COLLABORATIONS WITH PRESTIGIOUS RESEARCH TEAMS, HOSPITALS, AND RESEARCH CENTERS NATIONWIDE AND; (III) LEVERAGED NEW TECHNOLOGIES TO IMPROVE, ALTER CANCER TRAJECTORIES, AND CONSTANTLY CHALLENGE THE FOUNDATION OF CANCER CARE.

OUR FOUNDATION FUNDED TWO SIGNIFICANT RESEARCH PROJECTS STEMMING FROM THE SIDE OUT 3 CLINICAL TRIAL, FOCUSING ON IDENTIFYING MOLECULAR BIOMARKERS THAT INDICATE NON-RESPONSE TO FIRST-LINE ENDOCRINE TREATMENT WITH CDK4/6 INHIBITORS (LIKE IBRANCE) IN ER+/HER2- METASTATIC BREAST CANCER (MBC) PATIENTS. THROUGH OUR FUNDED LABORATORY RESEARCH, WE ARE DEVELOPING AN INNOVATIVE THERAPEUTIC APPROACH FOR PATIENTS LIKELY TO PROGRESS BEYOND STANDARD CARE. THE PROMISING PRECLINICAL DATA CONTINUES TO VALIDATE CLINICAL OBSERVATIONS, POSITIONING US TO ESTABLISH A GROUNDBREAKING CLINICAL TRIAL OFFERING NOVEL THERAPEUTIC OPTIONS TO MBC PATIENTS WHO DON'T BENEFIT FROM STANDARD CARE. TO OUR KNOWLEDGE, THIS THERAPEUTIC APPROACH WOULD BE THE FIRST OF ITS KIND FOR MBC PATIENTS.ADDITIONALLY, THROUGH OUR PATIENT-CENTERED PRECISION MEDICINE INITIATIVE CONTRACTED TO PERTHERA, WE CONDUCTED AN INTERIM ANALYSIS USING REAL-WORLD DATA FROM ENROLLED PATIENTS. THIS RESEARCH DEMONSTRATED THE EFFECTIVENESS OF A MULTI-OMIC APPROACH IN PREDICTING DRUG TARGET ACTIVATION AND TREATMENT RESPONSE IN INDIVIDUAL PATIENTS. OUR FUNDED RESEARCH, PUBLISHED IN THE "BRITISH JOURNAL OF CANCER," SHOWED THAT COMBINING GENOMIC, PROTEOMIC, AND PHOSPHOPROTEOMIC DATA MAY BETTER IDENTIFY PATIENTS SUITABLE FOR THE NEWLY FDA-APPROVED SECOND-LINE TREATMENT, CAPIVASERTIB, COMPARED TO USING GENOMIC DATA ALONE. THIS YEAR'S COMPREHENSIVE RESEARCH EFFORTS HAVE SIGNIFICANTLY ADVANCED THE UNDERSTANDING OF MBC BIOLOGY, ENHANCED DIAGNOSTIC APPROACHES AVAILABLE TO PHYSICIANS FOR TAILORING MBC PATIENT TREATMENTS, AND INITIATED PRECLINICAL TESTING OF PROMISING NEW THERAPEUTIC OPTIONS SPECIFICALLY FOR PATIENTS AFFECTED BY ER+/HER2- MBCS.